Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Double or Triple Hit Lymphoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well polatuzumab vedotin and combination chemotherapy work in
treating patients with previously untreated double or triple hit lymphoma. Polatuzumab
vedotin is a monoclonal antibody that works by binding with cancer cells and releasing
another chemotherapy drug, called monomethyl auristatin E, into the cell causing the cancer
cells to die or stop growing. Chemotherapy drugs, such as rituximab, cyclophosphamide,
doxorubicin, and prednisone, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving polatuzumab vedotin with combination chemotherapy may work better in
treating patients with double or triple hit lymphoma compared to combination chemotherapy
alone.